These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29325276)

  • 1. [A clinical study of antiviral therapy for patients with compensated hepatitis C cirrhosis].
    Xie ZW; Li JP; Guan YJ; Zhang XY; Guo FX; Chen BB; Pan CQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):827-833. PubMed ID: 29325276
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
    Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
    Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
    Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():327-34. PubMed ID: 27051280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
    D'Ambrosio R; Aghemo A; Rumi MG; Primignani M; Dell'Era A; Lampertico P; Donato MF; De Nicola S; Prati GM; de Franchis R; Colombo M
    Antivir Ther; 2011; 16(5):677-84. PubMed ID: 21817189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].
    Ji F; Dang S; Cai Z; Xue H; Huang N; Liu L; Zhang S; Guo Y; Jia X; Wang Y; Li Z; Deng H
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):647-52. PubMed ID: 26524356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
    Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
    J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin?
    de Segadas-Soares JA; Villela-Nogueira CA; Perez RM; Nabuco LC; Brandão-Mello CE; Coelho HS
    J Clin Gastroenterol; 2009 Apr; 43(4):362-6. PubMed ID: 19077732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
    Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
    Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
    Giannini EG; Basso M; Savarino V; Picciotto A
    J Intern Med; 2009 Dec; 266(6):537-46. PubMed ID: 19849774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
    Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
    [No Abstract]   [Full Text] [Related]  

  • 17. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.
    Butt AS; Mumtaz K; Aqeel I; Shah HA; Hamid S; Jafri W
    Trop Gastroenterol; 2009; 30(4):207-12. PubMed ID: 20426280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.
    Iacobellis A; Ippolito A; Andriulli A
    World J Gastroenterol; 2008 Nov; 14(42):6467-72. PubMed ID: 19030197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.